MKS Instruments (MKSI) Tops Q4 EPS by 17c, provides guidance

MKS Instruments (NASDAQ: MKSI) reported Q4 EPS of $2.47, $0.17 better than the analyst estimate of $2.30. Revenue for the quarter came in at $1.03 billion versus the consensus estimate of $995.32 million.

GUIDANCE:

MKS Instruments sees Q1 2026 EPS of $2.00, plus or minus $0.28, versus the consensus of $1.87. MKS Instruments sees Q1 2026 revenue of $1040 million, plus or minus $40 million, versus the consensus of $1008 million.

For earnings history and earnings-related data on MKS Instruments (MKSI) click here.

You May Also Be Interested In

• Outlook Therapeutics (OTLK) Misses Q3 EPS by 9c
• Tvardi Therapeutics (TVRD) Tops Q2 EPS by 1c
• Morgan Stanley sees limited gas regulation impact on utilities